Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

NCT01188967 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Nicotine Dependence

Interventions

DRUG: GSK598809
DRUG: Placebo

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]